AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This ...

AIM ImmunoTech Inc. announced plans to advance its drug Ampligen as a vaccine adjuvant for avian influenza, marking a new initiative in its antiviral development pipeline. The company has ...

AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

Vaccination bills are popping up in more than 15 states as lawmakers aim to potentially resurrect or create new religious ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

The bills would restrict how employers treat vaccination and require a reporting system for "vaccine injuries." ...

HONG KONG SAR – media OutReach Newswire – 5 February 2025 – AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV ...

(MENAFN- Dubai PR Network) data-text="AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S." data-link=" Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S." class ...

The issuer is solely responsible for the content of this announcement.